Cytokinetics (CYTK) Q2 2024 earnings summary

Executive summary

• Significant progress in late-stage clinical programs, especially aficamten, with strong SEQUOIA-HCM results presented and published, supporting a next-in-class profile for HCM treatment and upcoming regulatory filings.

• Productive regulatory interactions with FDA, EMA, and Chinese authorities, with rolling NDA submission for aficamten initiated and MAA planned for Q4 2024.

• Strengthened balance sheet with $1.4B in cash and investments after equity and strategic financing, supporting commercial launch and pipeline advancement.

• Expanded specialty cardiology franchise with ongoing and planned trials for aficamten, omecamtiv mecarbil, and CK-586.

• Secured contingent access to over $1 billion in funding to support aficamten's global launch and pipeline advancement.

Financial highlights

• Ended Q2 2024 with $1.4B in cash, up from $634.3M in Q1, driven by $563.2M equity raise and $250M from Royalty Pharma.

• Q2 2024 revenues were $0.2M, down from $0.9M year-over-year, primarily from Ji Xing collaboration agreements.

• R&D expenses were $79.6M (down from $83.2M), G&A expenses rose to $50.8M (from $39.7M), reflecting commercial readiness investments.

• Net loss was $143.3M ($1.31/share), compared to $128.6M ($1.34/share) in Q2 2023.

• Operating expenses for Q2 2024 were $130.4M, up from $122.9M in Q2 2023, driven by increased G&A costs.

Outlook and guidance

• 2024 GAAP operating expenses expected at $555M–$575M, up from prior guidance; non-GAAP operating expenses forecasted at $445M–$470M.

• Net cash utilization projected based on year-end cash balance of $1,142–$1,162M.

• Rolling NDA submission for aficamten to complete in Q3 2024; MAA to EMA in Q4 2024; China NDA planned for H2 2024.

• MAPLE-HCM enrollment to complete in Q3 2024; ACACIA-HCM and CEDAR-HCM enrollment ongoing; omecamtiv mecarbil Phase 3 trial to start in Q4 2024.

• Management expects existing cash and investments to fund operations for at least the next 12 months.